Hans K Hasselbalch

Hans K Hasselbalch

Clinical Professor

Member of:

  • Internal Medicine: Haematology


Publication year:
All
71 - 80 out of 133Page size: 10
Sort by: 1st author
  1. Published

    The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

    Holmstrom, M. O., Martinenaite, E., Ahmad, S. M., Met, Özcan, Friese, C., Kjaer, L., Riley, C. H., Straten, P. T., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 1 Feb 2018, In: Leukemia. 32, 2, p. 429-437

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

    Holmstrom, M. O., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2017, In: OncoImmunology. 6, 11, 3 p., e1358334.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

    Holmström, M. O., Riley, C. H., Skov, V., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2018, In: OncoImmunology. 7, 6, e1433521.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

    Holmström, M. O., Hjortso, M. D., Ahmad, S. M., Met, Özcan, Martinenaite, E., Riley, C., Straten, P., Svane, Inge Marie, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2017, In: Leukemia. 31, p. 495-498

    Research output: Contribution to journal › Letter › Research › peer-review

  5. Published

    Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

    Holmström, M. O., Cordua, S., Skov, V., Kjær, L., Pallisgaard, N., Ellervik, Christina, Hasselbalch, Hans Carl & Andersen, Mads Hald, 2020, In: Cancer Immunology, Immunotherapy. 69, p. 315–324

    Research output: Contribution to journal › Review › Research › peer-review

  6. Published

    Terapeutisk cancervaccination mod hæmatologisk cancer

    Holmström, M. O., Grauslund, J. H., Dahlager-Jørgensen, N. G., Klausen, U., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2019, In: Ugeskrift for Laeger. 181, 20A, 5 p., V04190233.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Cancer immune therapy for Philadelphia chromosome-negative chronic myeloproliferative neoplasms

    Holmström, M. O., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2020, In: Cancers. 12, 7, p. 1-21 21 p., 1763.

    Research output: Contribution to journal › Review › Research › peer-review

  8. Published

    Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

    Holmström, M. O., Novotny, G. W., Petersen, J., Aaboe-Jørgensen, M., Hasselbalch, Hans Carl, Andersen, Mads Hald, Nielsen, S. L., Fassi, Daniel El & Schöllkopf, C., 2019, In: Leukemia and Lymphoma. 60, 13, p. 3296-3299

    Research output: Contribution to journal › Letter › Research › peer-review

  9. Published

    Cancer immune therapy for myeloid malignancies: present and future

    Holmström, M. O. & Hasselbalch, Hans Carl, 2019, In: Seminars in Immunopathology. 41, 1, p. 97-109

    Research output: Contribution to journal › Review › Research › peer-review

  10. Published

    Neo-antigen specific memory T-cell responses in healthy individuals

    Holmström, M. O., Hasselbalch, Hans Carl & Andersen, Mads Hald, 2019, In: OncoImmunology. 8, 7, 2 p., 1599640.

    Research output: Contribution to journal › Letter › Research › peer-review

Previous 1...4 5 6 7 8 9 10 11 ...14 Next

ID: 2849472